CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Companyâs product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.

Employees

647

Sector

Biotechnology & Medical Research

Calendar

Apr. 30 - Q1 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
25-04-17	17.70 $	-2.83%	210,858
25-04-16	18.22 $	-4.91%	507,044
25-04-15	19.16 $	+1.38%	460,383
25-04-14	18.90 $	+0.48%	671,321
25-04-11	18.81 $	+2.06%	689,916

Delayed Quote Nasdaq, April 17, 2025 at 01:29 pm EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

18.22USD

Average target price

31.36USD

Spread / Average Target

+72.10%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 01:46:04 2025-04-17 pm EDT			5-day change	1st Jan Change
17.76 ^USD	-2.52%		-3.96%	-17.33%

Mar. 11	CareDx, Inc Launches Two Expanded Indications for AlloSure Testing Services	CI
Feb. 26	CareDx, Inc, Q4 2024 Earnings Call, Feb 26, 2025

Capitalization	1.01B 888M 827M 762M 1.4B 86.24B 1.58B 9.72B 3.8B 38.44B 3.79B 3.71B 144B	P/E ratio 2025 *	-42.6x	P/E ratio 2026 *	1,458x
Enterprise value	883M 777M 724M 666M 1.22B 75.44B 1.38B 8.5B 3.33B 33.63B 3.31B 3.25B 126B	EV / Sales 2025 *	2.38x	EV / Sales 2026 *	1.96x
Free-Float	96.56%	Yield 2025 *	-	Yield 2026 *	-

CareDx, Inc Launches Two Expanded Indications for AlloSure Testing Services	Mar. 11	CI
CareDx, Inc, Q4 2024 Earnings Call, Feb 26, 2025	Feb. 26
Earnings Flash (CDNA) CAREDX INC. Reports Q4 Revenue $86.6M, vs. FactSet Est of $84.1M	Feb. 26	MT
Earnings Flash (CDNA) CAREDX INC. Reports Q4 Adjusted EPS $0.18	Feb. 26	MT
CareDx, Inc announces an Equity Buyback for $50 million worth of its shares.	Feb. 26	CI
CareDx, Inc. Provides Revenue Guidance for the Full Year 2025	Feb. 26	CI
CareDx, Inc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	Feb. 26	CI
CareDx, Inc. Announces Study Showing Alloseq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients	Feb. 20	CI
CareDx, Inc authorizes a Buyback Plan.	Jan. 31	CI
CareDx Shares Rise Following Upgrade From Wells Fargo	Jan. 15	MT
Wells Fargo Upgrades CareDx to Equalweight From Underweight, Adjusts Price Target to $24 From $28	Jan. 15	MT
CareDx, Inc Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 04:30 PM	Jan. 14
CareDx, Inc Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2024 and Provides Revenue Guidance for the Year 2025	Jan. 13	CI

Wells Fargo Upgrades CareDx to Equalweight From Underweight, Adjusts Price Target to $24 From $28	Jan. 15	MT
Wells Fargo Initiates CareDx at Underweight With $28 Price Target	24-08-28	MT
Nephron Initiates CareDx at Hold Rating With $15 Price Target	24-07-10	MT
Craig-Hallum Adjusts Price Target on CareDx to $22 From $15, Maintains Buy Rating	24-05-17	MT
Raymond James Downgrades CareDx to Market Perform From Outperform	24-05-14	MT

CareDx, Inc Stock

Equities

CDNA

US14167L1035

Biotechnology & Medical Research

Valuation: CareDx, Inc

Chart: CareDx, Inc

Latest news: CareDx, Inc

Last Transcript: CareDx, Inc

Analysts' recommendations: CareDx, Inc

Press Releases: CareDx, Inc

News in other languages: CareDx, Inc

Quotes and Performance

Course Extremes

Managers and Directors: CareDx, Inc

ETFs: CareDx, Inc

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

CareDx to Report First Quarter 2025 Financial Results	Apr. 08	BU
CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA	Mar. 28	BU
CareDx Launches Two Expanded Indications for AlloSure Testing Services	Mar. 11	BU
CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA	Mar. 04	BU
CareDx: Q4 Earnings Snapshot	Feb. 26	AQ

CareDx anuncia un estudio que demuestra la alta precisión de AlloSeq cfDNA en la detección del rechazo en pacientes con trasplante de órganos	Feb. 20
CareDx publie une étude confirmant la grande précision d’AlloSeq cfDNA dans la détection du rejet chez les patients transplantés	Feb. 20
CareDx gibt Studie bekannt, die zeigt, dass AlloSeq cfDNA bei der Erkennung von Abstoßungsreaktionen bei Organtransplantationspatienten äußerst genau ist	Feb. 20
CareDx et ses collaborateurs présentent les dernières avancées dans le domaine cardio-thoracique lors de la réunion 2024 de la Société internationale de transplantation cardiaque et pulmonaire	24-04-09
CareDx und Mitarbeiter präsentieren neueste Herz-Thorax-Fortschritte im Rahmen des 2024 International Society for Heart and Lung Transplantation Meeting	24-04-09

1 day	-2.88%
1 week	-3.96%
Current month	-0.28%
1 month	-8.15%
3 months	-17.44%
6 months	-27.70%
Current year	-17.33%

Manager	Title	Age	Since
John Hanna CEO	Chief Executive Officer	45	2024-04-14
Abhishek Jain DFI	Director of Finance/CFO	49	2022-05-25
Keith Kennedy COO	Chief Operating Officer	55	2024-09-11

Director	Title	Age	Since
Michael Goldberg CHM	Chairman	67	2021-10-31
Peter Maag CHM	Chairman	58	2019-12-31
George Bickerstaff BRD	Director/Board Member	69	2014-04-07

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CAREDX, INC	-2.88%	-3.96%	+113.77%	-45.62%	1.01B
EXACT SCIENCES CORPORATION	-0.66%	-4.08%	-33.64%	-38.16%	7.85B
BGI GENOMICS CO., LTD.	-0.73%	-1.01%	+26.15%	-37.04%	2.52B
VERACYTE, INC.	-1.41%	+2.21%	+63.94%	+32.93%	2.46B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	0.00%	-3.30%	+206.15%	-27.69%	1.11B
IOVANCE BIOTHERAPEUTICS, INC.	-1.47%	-2.78%	-74.79%	-81.59%	1.01B
SEEGENE, INC.	0.00%	+7.78%	+15.48%	-41.71%	791M
CURIOX BIOSYSTEMS CO., LTD	+0.87%	+24.19%	+6.57%	-	261M
MARAVAI LIFESCIENCES HOLDINGS, INC.	-0.87%	-4.21%	-77.94%	-95.05%	247M
3BILLION, INC.	+1.64%	+28.87%	-	-	150M
Average	-0.56%	-1.53%	+27.30%	-41.74%	1.74B
Weighted average by Cap.	-0.84%	-5.05%	+12.90%	-31.03%

	2025 *	2026 *
Net sales	371M 326M 304M 280M 514M 31.67B 581M 3.57B 1.4B 14.12B 1.39B 1.36B 52.72B	427M 375M 350M 322M 592M 36.45B 669M 4.11B 1.61B 16.24B 1.6B 1.57B 60.67B
Net income	-24.14M -21.23M -19.78M -18.21M -33.47M -2.06B -37.84M -232M -90.89M -919M -90.58M -88.68M -3.43B	673K 592K 551K 508K 933K 57.49M 1.06M 6.48M 2.53M 25.62M 2.53M 2.47M 95.69M
Net Debt	-126M -111M -104M -95.38M -175M -10.8B -198M -1.22B -476M -4.81B -474M -464M -17.97B	-175M -154M -144M -132M -243M -14.96B -275M -1.69B -660M -6.67B -657M -644M -24.91B